Background: Large thrombotic burden is a well-known predictor of no-reflow phenomenon and mortality in ST-elevation myocardial infarction (STEMI). However, limited data are available on the clinical significance of residual thrombus after thrombectomy. Therefore, we aimed to investigate the effectiveness of manual thrombectomy in decreasing thrombus burden, and the effect of residual thrombus on myocardial perfusion after thrombectomy. Methods: A multicenter, randomized, prospective trial including 479 acute myocardial infarction (MI) patients was conducted to compare the efficacy and safety of the everolimus-and zotarolimus-eluting stents for coronary lesions. After excluding 197 non-STEMI patients, 283 STEMI patients undergoing primary percutaneous intervention (PCI) were studied. The no-reflow phenomenon incidence after primary PCI was compared between the small thrombus burden (n¼138) and large thrombus burden (n¼145) groups, defined by a thrombus score of 3. Aspiration thrombectomy was performed in 71 large thrombus group patients (49%), and the no-reflow incidence in this group was compared based on thrombectomy treatment and pre-stenting residual thrombus. No-reflow phenomenon was defined by a final TIMI flow grade of 2 or myocardial blush grade of 1. Results: No-reflow phenomenon occurred frequently in the large thrombus burden patients without thrombectomy, followed by those who underwent thrombectomy, and the small thrombus burden group (33.8% vs. 18.9% vs. 10.1%, p<0.001). Fifteen patients with pre-stenting residual thrombus had a higher no-reflow incidence than those without visible pre-stenting thrombus (66.7% vs. 15.7%, p<0.001). Multilogistic analysis revealed a baseline TIMI flow grade of 1 (odds ratio [OR] 2.929, confidence interval [CI] 1.064-8.062), Killip class 2 or 3 (OR 2.452, CI 1.100-5.466), pre-stenting residual thrombus (OR 7.997,, and distal embolization (OR 3.859, CI 1.252-11.893) were independent no-reflow phenomenon predictors. Conclusions: Aspiration thrombectomy substantially reduces no-reflow phenomenon incidence in STEMI patients with large thrombus burden. However, residual thrombus after thrombectomy increases no-reflow phenomenon occurrence.
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Low Background: Despite initial data of efficacy, concerns were raised regarding the risk of increased very late stent thrombosis (VLST) using first generation drug eluting stents (DES) compared to bare metal stents in patients with ST-elevation acute myocardial infarction (STEMI). Though second generation DES have shown even increased efficacy and lower rates of VLST in stable angina patients, no randomized data was available in STEMI. The XAMI trial (XienceV stent vs Cypher stent in primary PCI for Acute Myocardial Infarction) is the first randomized trial presenting three year follow-up data of second generation DES in STEMI patients. Methods: 625 patients (all-comers) treated with primary PCI for STEMI were randomized 2:1 to everolimus-eluting stents (EES) or sirolimus-eluting stents (SES). Exclusion criteria were minimal. The primary endpoint was major adverse cardiac events (MACE), consisting of cardiac death, non-fatal myocardial infarction or any target vessel revascularization (TVR) at one year. Secondary endpoints included MACE at 3 years and stent thrombosis rates. Results: At one year, non-inferiority of the primary endpoint was shown: 4.0% (EES) versus 7.7% (SES) (p ¼ 0.048), suggesting superiority of the EES. Definite and/or probable stent thrombosis rate was low, 1.2% (EES) versus 2.7% (SES) (p¼0.21). Radial approach was used in over 50 % of patients as was thrombus aspiration. First medical contact to balloon inflation time was a median of only 75 minutes. At three years, MACE rate was 8.0% (EES) versus 10.5% (SES) (p¼0.30). Cardiac death rate was low at 2.5% (EES) versus 2.7% (SES) (p¼0.86) as was overall target lesion revascularization (TLR) rate at 2.3%. Definite and/or probable stent thrombosis rate between one and three year was low with 1.1% for EES and only 0.5% for SES. Conclusions: This contemporary all-comer STEMI trial showed very low cardiac mortality, TLR and stent thrombosis rates at three year follow-up with both first and second generation DES. With these low event rates no advantage of second generation DES could be seen. Background: Primary PCI for STEMI may lead to rapid washout of CK-MB. There is insufficient information correlating peak CK-MB to infarct size. Methods: NFUSE-AMI randomized pts with anterior STEMI undergoing bivalirudin supported primary PCI to intralesion abciximab vs. no abciximab and to manual thrombus aspiration vs. no aspiration. In 311 pts left ventricular (LV) ejection fraction (EF) and infarct size (as a percentage of total LV mass) were evaluated by cardiac magnetic resonance imaging (cMRI) at 30 days and compared to peak CK-MB. Pts were clinically followed for 1-year. Results: Median peak CK-MB was 240 IU/L (IQR: 126 to 414) which was strongly correlated with infarct size evaluated by cMRI (Figure) . Pts in the highest peak CK-MB tertile had significantly larger infarct size (32.3% vs. 21.7% vs. 5.7%, p<0.001) and lower LVEF (41.5% vs. 48.4% vs. 52.1%, p<0 .001) than patients in the middle and lowest tertiles. Peak CK-MB of 200 IU/L predicted both a large infarct size (>20% of LV mass: sensitivity 94%, AUC 0.86) and LVEF <40% (sensitivity 91%, AUC 0.78). Furthermore, peak CK-MB was an independent predictor of 1-year 
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